23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018...
17:36 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting CBLC could help treat EGFR-mutant NSCLC. In two human EGFR-mutant NSCLC cell lines, two shRNAs targeting CBLC decreased viability compared with a...
19:50 , Aug 18, 2017 |  BC Week In Review  |  Company News

Aslan and Academia Sinica combine ASLAN003 and varlitinib in animal models

Aslan Pharmaceuticals Ltd. (TPEx:6497) and Academia Sinica (Taipei, Taiwan) partnered to evaluate the the combination of varlitinib ( ASLAN001 ) and ASLAN003 in animal models for gastric, colorectal and lung cancers. The partners said the...
22:01 , Apr 4, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Patient sample, cell culture and mouse studies suggest inhibiting HER2 could help treat AD. In postmortem hippocampal tissue samples, levels of HER2 were higher in samples from sporadic AD patients than...
19:08 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest promoting DAXX expression could help treat lung cancer. In patients with non-small cell lung cancer (NSCLC) tumors that overexpressed the metastasis-promoting SNAI2 gene, low...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting TIFA could help treat AML. In peripheral blood mononuclear cells (PBMCs) from AML patients, levels of TIFA were higher in than...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Galectin-4 (LGALS4)

Cancer INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting LGALS4 could help treat prostate cancer. In patient tumor samples, high levels of LGALS4 expression were associated with high rates of cancer...
07:00 , Aug 1, 2016 |  BioCentury  |  Finance

Disrupting detection

Following the validation and Taiwan launch of CRC-Protect, CellMax Life Inc. has convinced Artiman Ventures to return for seconds and lead a $9 million series A-1 round. The funding will enable the California company to...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)

Cancer INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting GD3 ganglioside or its synthetic enzyme ST8SIA1 could help treat glioblastoma multiforme (GBM). In patients, tumor levels of GD3 ganglioside and ST8SIA1...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HCV NS5A protein

Infectious disease INDICATION: Hepatitis C virus (HCV) Cell studies suggest disulfiram could help treat HCV by preventing Zn2+-dependent activity of HCV NS5A. In an in vitro assay, disulfiram displaced Zn2+ from HCV NS5A. In a...